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Abstract: Background: Proliferation is a distinct hallmarks of cancer. Ki-67 designated as a marker of proliferation in solid 
tumors. The proliferative activity of tumor demonstrated by expression of Ki-67 in breast cancer has been associated with a 
poor prognosis. Changes in the relative proportions of Ki-67 can be observed during chemotherapy and may correlated with 
clinical response in breast cancer. Purpose: Evaluate changes in mRNA expression of proliferation marker Ki-67 in breast 
cancer patients pre- and post-chemotherapy in relation with clinical response to chemotherapy. Method: This is a longitudinal 
study, 30 subjects breast cancer tissue samples pre- and post-chemotherapy using cyclophosphamide, adriamycin, 5FU 
regiment. We using qRT-PCR techniques to detect mRNA expression of Ki-67. Chemotherapy response is calculated using 
RECIST criteria. Results: Mean value of Ki-67 mRNA expression on breast cancer patients pre-chemotheraphy was 
11.837±0.360. Mean value of Ki-67 mRNA expression on breast cancer patients post-chemotheraphy was 11.241±1.971. There 
was no significant correlation between expression of Ki-67 mRNA prechemotherapy with clinical response to chemotherapy, p 
= 0.862 (p ≥0.05). There is a positive correlation between velocity of Ki-67 mRNA expression with clinical response with 
value of r = 0.378, this correlation was significant with p = 0.020 (p<0.05). Conclusion: Chemotherapy cause decrease in 
mRNA expression of Ki-67. There is insignificant correlation between expression of mRNA Ki-67 baseline with chemotherapy 
response. Velocity of Ki-67 mRNA expression has significant correlation with clinical response to chemotherapy. 
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1. Introduction 
Proliferation has been recognized as a distinct hallmark of 
cancer [1]. Ki-67 is a core protein that is expressed on the 
cell being proliferated and the level of expression changes 
throughout the cell cycle [2]. Ki-67 is expressed below 3% in 
healthy breast tissue. Ki-67 proliferation index has prognostic 
and predictive benefit in breast cancer [3]. Several studies 
have found changes in the expression of Ki-67 pre- and post-
chemotherapy become a strong and independent predictor of 
the disease-free period and survival. This is the reason that 
the tumor response in many neoadjuvant chemotherapy trials 
are now evaluated by examination of Ki-67 in 
immunohistochemistry [4]. The problem of using 
immunohistochemistry for Ki-67 is the lack of consensus on 
the cut-off value of Ki-67 for the administration of 
chemotherapy and there seems to be a gray zone [5]. Some 
Studies reveal that mRNA expression of Ki-67 seems to be 
more robust and meaningful than the determination based on 
the Ki-67 protein by immunohistochemistry, either by visual 
scoring or quantitative image analysis [6]. The aim of this 
study was to evaluate mRNA expression of Ki-67 pre- and 
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post-chemotherapy in associations with breast cancer 
chemotheraphy response. 
2. Materials and Method 
2.1. Collection of Samples 
Study was conducted within a population of breast cancer 
patients who had been diagnosed through clinical and 
histopathology examination, which entered the Wahidin 
Sudirohusodo Hospital in Makassar, South Sulawesi, 
Indonesia. Inclusion criteria were female patients with locally 
advanced breast cancer and histopathological type of 
invasive ductal carcinoma. Exclusion criteria was inadequate 
tissue samples and patient had been undergoing 
chemotherapy, targeting therapy or hormonal therapy. 
All samples who fulfilled inclusion and exclusion criteria 
and willing to participate in the study and signing informed 
consent. The samples consisted of 30 patients with breast 
cancer who have undergone combinations chemotherapy of 
cyclophosphamide, adriamycin and 5FU manufactured by 
Kalbe Farma Indonesia. Chemotherapy was prescribed by 
official doctors.  
2.2. Immunohistochemistry Examination 
Evaluation of estrogen and progesterone receptors (ER, 
PR) and HER2 expression by immunohistochemistry are 
routinely performed in breast carcinomas in our hospitals. 
Immunohistochemistry was performed, following epitope 
retrieval, with a polymer based detection system (Envision 
plus, Dako, Carpinteria, CA) using mouse monoclonal 
antibodies for ER and PR (Dako, Carpinteria, CA), ER (1D5; 
1:50), PR (PgR636; 1:400), and Herceptin kit (HercepTest, 
Dako, Carpinteria, CA) according to the manufacturer's 
instructions [7]. 
2.3. Nucleic Acid Isolation 
Nucleic acid was extracted from breast cancer tissue 
according to the diatom guanidinium isothiocyanate 
(GuSCN) method described by Boom et al. 1990. Breast 
cancer tissue was mixed with 500µl of lysis buffer L6 
(50mMTris-HCl, 5.25M GuSCN, 20mM EDTA, 0.1% Triton 
X100), vortexes vigorously, and centrifuged at 1,000 rpm for 
5min. To obtain the nucleic acid, samples were lysed by 
incubation for 15 minutes at 18°C and 20µl of diatom 
suspension was added. The diatom containing the bound 
nucleic acid was centrifuged at 12,000 x g for 15 seconds to 
obtain diatom pellet. The diatom pellet was then washed with 
washing buffer L2 (5.25M GuSCN in 0.1M Tris-HCl, 
pH6.4), rinsed with 70% ethanol and acetone, and dried by 
incubation at 56°C for 10 minutes. The pellet was mixed with 
60µl of 10mM Tris-HCl, pH 8.0, 1mM EDTA buffer and the 
nucleic acid was eluted by incubation at 56°C for 10 minutes. 
After sedimentation of the diatom by centrifugation, the 
supernatant was collected and stored at -20°C until Real- 
Time PCR was performed [8]. 
2.4. Expression mRNA Ki-67 Genes by Real Time PCR 
Detection of mRNA expression of Ki-67 was done 
according to Real time PCR method previously describe by 
Mitas, 2001 and Potemski, 2006. Specific primers for mRNA 
Ki-67 were used: Ki-67 forward: TCCTTTGGTGGGCA 
CCTAAGACCTG and Ki-67 reverse: TGATGGTTGAG 
GTCGTTCCTTGATG. Cycle RT PCR for Ki-67 was 94°C 
for 3 minute; 94°C for 30 second 38 cycles and next step is 
PCR: 51°C for 30 second. Also, specific primers of 
housekeeping genes were used GAPDH forward: TGAGT 
GCTGTCTCCATGTTTGA and GAPDH reverse: TCTGC 
TCCCCACCTCTAAGTTG. [9, 10] 
2.5. Data Analysis 
Data analysis using the SPSS (Statistical Package for 
Social Science) version 22. Normality of the samples were 
analyzed using shapiro wilk’s test. Analysis of patient’s 
characteristics and clinical response using chi square. 
Analysis of mean difference of Ki-67 mRNA expression 
between responsive and nonresponsive groups used wilcoxon 
test, to see the correlation using the pearson and spearman 
test.  
2.6. Ethical Clearence 
Ethical approval for this study was obtained from Research 
Ethics Committee, Faculty of Medicine, Hasanuddin 
University, Makassar, Indonesia. 
3. Results 
During the period from July 2015 to August 2016 acquired 
research subjects were 30 patients with breast cancer which 
meet the inclusion criteria. Minimum age of subject was 28 
years and maximum was 64 years old, the mean age of 
subjects in this research was 50.3 years. Analysis of the age 
factor to clinical response to chemotherapy between age ≤50 
years and >50 years, statistically no significant with p=0.581 
(p>0.05). Histopathologic grading obtained Low grade 2 
cases (6.7%), Moderate grade 19 cases (63.3%) and High 
grade 9 (30%). Analysis of the grade factor to clinical 
response to chemotherapy between low, moderate and high 
grade, no significant statistically with p=0.408 (p>0,05). 
Immunohistochemistry examination panel obtained subtypes 
luminal 16/30 (56.6%), Her2 8/30 (26.6%) and triple 
negative 6/30 (20%). Analysis of the Imunohistochemistry 
profile with clinical response to chemotherapy, no significant 
statistically with ER p=0.060 (p>0,05), PR p=0.515 
(p>0,05), Her2 p=0.340 (p>0,05). The clinical response to 
neoadjuvant chemotherapy; responsive as much as 23/30 
(76.7%) and nonresponsive 7/30 (23.3%). 
Table 1. Patients characteristic. 
Characteristic n (%) 
Age  
≤ 50 14 (46,7%) 
> 50 16 (53,3%) 
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Characteristic n (%) 
Grade  
Low Grade 2 (6,7%) 
Moderate Grade 19 (63,3%) 
High Grade 9 (30 %) 
Immunohistochemistry  
ER 8 (26,7%) 
PR 11 (36,6%) 
HER2 17 (56,6%) 
Clinical response  
Responsive 23 (76,7%) 
Nonresponsive (23,3%) 
Mean value of Ki-67 mRNA on breast cancer patients 
prechemotheraphy which responsive to chemotherapy was 
11.830±0.334 whereas on nonresponsive was 11.858±0.466. 
Mean value of Ki-67 mRNA on breast cancer patients post 
chemotheraphy which responsive to chemotherapy was 
10.862±1.965, whereas on nonresponsive was 12.487±1.501. 
In the responsive group expression of Ki-67 mRNA tend to 
decreased by 0.97. In the group nonresponsive expression of 
Ki-67 mRNA likely to increase by 0.63. There was no 
significant correlation between expression of Ki-67 mRNA 
prechemotherapy with clinical response to chemotherapy, p = 
0.862(p ≥0.05). There was no significant correlation between 
expression of Ki-67 mRNA postchemotherapy with clinical 
response to chemotherapy, p = 0.054 (p ≥0.05).  
Table 2. Comparison expression of mRNA Ki-67 pre- and post-chemotherapy with clinical response. 
mRNA Expression Responsive (n=23) Non Responsive (n=7) Mean difference p* 
Ki-67 (Prechemoterapy) 11.83 ± 0.33 11.85 ± 0.46 0.02 0.862 
0.054 Ki-67 (Postchemoterapy) 10.86 ± 1.96 12.48 ± 1.50 1.62 
Mean difference 0.97 -0.63   
p = * Wilcoxon test 
Table 3. Correlations expression of mRNA Ki-67 pre- and post-chemotherapy, velocity of mRNA Ki-67 and chemotherapy response. 
 mRNA Expression (Mean±SD) Correlation with Chemotherapy response (r) p 
mRNA Ki-67 (prechemotherapy) 11.837±0.360 0.028 0.885 * 
mRNA Ki-67 (Postchemotherapy) 11.241±1.971 -0.368 0.046 ** 
Velocity mRNA Ki-67 5.021±16.438 0.378 0.039 ** 
p = * pearson ** spearman  
There is a positive correlation between mRNA expression 
of Ki-67 prechemotherapy with clinical response with value 
of r = 0.028, this correlation was insignificant with p = 0.885 
(p>0.05). There is a negative correlation between mRNA 
expression of Ki-67 postchemotherapy with clinical response 
with value of r =- 0.368, this correlation was significant with 
p = 0.046 (p<0.05). There is a positive correlation between 
velocity of Ki-67 mRNA expression with clinical response 
with value of r = 0.378, this correlation was significant with 
p = 0.039 (p<0.05). 
4. Discussion 
In this research, the analysis of the age, grade and 
immunohistochemistry profiles with clinical response, found 
no significant relationship. Previous research found no 
relationship between age and pathological complete response 
[11, 12]. Some studies found grade does not relate to the 
numbers of pathological complete response, but significantly 
associated with disease free survival and overall survival of 
breast cancer patients receiving chemotherapy [11, 13]. 
Studies found poor response of anthracycline chemotherapy 
in immunohistochemistry of ER and PR positive. [14, 15] 
Previous studies found Her2 positive as predictor of 
anthracycline chemotherapy response [16, 17] 
Protein Ki-67 is a convenient and reproducible marker for 
solid cancer proliferation [1, 18]. Some literature mentions 
that the expression levels of Ki-67 were associated with poor 
prognosis [19]. St Gallen Consensus has recommended the 
use of the proliferation marker Ki-67, in determining optimal 
treatment strategies for early stage breast cancer [20]. 
Research has shown that the Ki-67 overexpression correlated 
with disease free survival and overall survival [21]. Tumors 
that have high levels of proliferation is have a better response 
to chemotherapy. However, in the multivariable analysis, not 
all studies show that baseline Ki-67 can be a predictor of 
pathological complete response. [22] Ki-67 themselves are 
not shown to predict the benefit of chemotherapy adjuvant 
cyclophosphamide, methotrexate and fluorouracil [23]. 
Baseline Ki-67 reported trend incremental benefits of taxane 
to anthracycline-based chemotherapy in high Ki-67 
compared lower Ki-67 cancer that warrants further 
investigation [24]. 
Tumors with Ki-67 mRNA expression were examined by 
qRT-PCR is associated with disease free survival and overall 
survival of patients treated with adjuvant chemotherapy 
regimen. The results showed that the tumor with Ki-67 
mRNA expression may be valuable for election patients for 
adjuvant therapy containing docetaxel [25]. 
Several studies have found changes in the expression of 
Ki-67 pre- and post-chemotherapy become a strong and 
independent predictor of the disease-free period and survival. 
This is the reason that the tumor response in many 
neoadjuvant chemotherapy trials are now evaluated by 
examination of Ki-67 in immunohistochemistry [4]. 
Studies found that the mRNA expression of Ki-67 was 
associated with a higher high pathological complete response 
rate of 36.4% compared with 5.8% in tumors with Ki-67 
mRNA levels are low. mRNA expression of Ki-67 were 
measured by qRT-PCR is predictive for the achievement of 
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pathological complete response for neoadjuvant 
chemotherapy and is superior to the Ki-67 expression was 
determined with immunohistochemistry [6]. qRT-PCR-based 
measurement of Ki-67 mRNA ensure an objective and highly 
reproducible quantification of proliferation activity of 
formalin-fixed paraffin-embedded (FFPE) tissue biopsy core 
of routine cut. Because it seems to be more robust and 
meaningful than the determination based on the Ki-67 protein 
by immunohistochemistry, either by visual scoring or 
quantitative image analysis. [6] 
5. Conclusion 
Chemotherapy cause decrease in mRNA expression of Ki-
67. There is insignificant correlation between expression of 
mRNA Ki-67 baseline with chemotherapy response. There is 
significant correlation between expression of mRNA Ki-67 
postchemotherapy with chemotherapy response. Consistently 
shown that the Ki-67 mRNA expression in the responsive 
group tended to decrease, whereas the mRNA expression of 
Ki-67 in the group that nonresponsive tends to increase. 
Velocity of Ki-67 mRNA expression has significant 
correlation with clinical response to chemotherapy. 
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